Summary
The economic consequences of the approximately 500 000 strokes that occur each year in the US are staggering. The direct cost of providing care for stroke victims in 1993 has been estimated to be $US 17 billion, with an additional $US 13 billion in indirect costs attributable to lost earnings due to stroke-related mortality and morbidity. Estimates of the cost of stroke over a patient’s lifetime vary according to age at first stroke and type of stroke. In 1990, these estimates ranged from $US91 000 for ischaemic stroke, $US124 000 for intracerebral haemorrhage, and $US228 000 for subarachnoid haemorrhage.
Factors driving the economics of stroke include the epidemiology of stroke, treatment patterns and settings, and social and behavioural factors. Evaluating the economic consequences of alternative interventions designed to prevent strokes or improve stroke outcomes involves a weighing of incremental costs and effectiveness. Previous efforts have focused primarily on measuring costs, with a recent shift to trying to measure patient preferences for stroke outcomes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Taylor TN, Davis PH, Torner JC, et al. Lifetime cost of stroke in the United States. Stroke 1996; 27: 1459–66
Broderick JP, Phillips EJ, Whisnant JP, et al. Incidence rates of stroke in the eighties: the end of the decline of stroke? Stroke 1989; 20: 577–82
Matchar DB, Duncan PW. Cost of stroke. Stroke Clin Updates 1994; 5: 9–12
Holloway RG, Witter DM, Lawton MA, et al. Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology 1996; 46: 854–60
Liebson CL, Hu T, Brown RD, et al. Utilization of acute care services in the year prior to and following first stroke: a population-based study. Neurology 1996; 46: 861–9
Lee AJ, Huber J, Stason WB. Poststroke rehabilitation in older Americans. The Medicare experience. Med Care 1996: 34: 811–25
Bergman L, van der Meulen JPH, Limburg M, et al. Costs of medical care after first-ever stroke in The Netherlands. Stroke 1996; 26: 1830–6
Kappelle LJ, Adams Jr HP, Heffner ML, et al. Prognosis of young adults with ischemic stroke. A long-term follow-up study assessing recurrent vascular events and functional outcome in the Iowa Registry of Stroke in Young Adults. Stroke 1994; 25: 1360–5
Hartunian NS, Smart CN, Thompson MS. The incidence and economic cost of cancer, motor vehicle injuries, coronary heart disease, and stroke. Am J Public Health 1980; 70: 1249–60
Australian Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including major submissions involving economic analyses. Canberra: Australian Government Publishing Service, 1995
Torrance GW, Blaker D, Detsky A, et al. Canadian guidelines for economic evaluation of pharmaceuticals. Pharmaco-Economics 1996; 9: 535
Solomon NA, Glick HA, Russo CJ, et al. Patient preferences for stroke outcomes. Stroke 1994; 25: 1721–5
Edgar MA, Schnieden H. The economics of mild hypertension programmes. Soc Sci Med 1989; 28: 211–22
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Taylor, T.N. The Medical Economics of Stroke. Drugs 54 (Suppl 3), 51–58 (1997). https://doi.org/10.2165/00003495-199700543-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199700543-00008